An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...
If it’s November, then it must be time for an issue of Endocrine News devoted entirely to the science and treatment of people living with diabetes to coincide with Diabetes Awareness Month in the United States. Each year we highlight the work of our members around the world and the research they conduct that contributes... Recent studies shed light on the safety and efficacy of diabetes medications GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors were all scrutinized in new research presented at ENDO 2024. While most of the results were good news for the impact of medications for people with type 2 diabetes, clinicians prescribing these medications should be...
New research explores the impact of prediabetes on a Mexican population. According to a study presented at ENDO 2024, prediabetes increases the risk of dying before the age of 75, particularly due to heart disease, kidney disease, and acute diabetic complications in Mexican populations. The study’s author, Carlos A. Fermín-Martínez, MD, discusses his findings and...
HDL Quality, Not Quantity, Contributes to the First Sign of Alzheimer’s Disease in Women
Higher levels of HDL-C—known as the “good cholesterol”—have been shown to correlate with heightened risk for Alzheimer’s disease, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Once women reach the menopause transition, it’s a matter of the quality, rather than quantity, of the total cholesterol carried by HDL particles circulating in a...
All the Rage: Combatting Counterfeit Weight-Loss and Diabetes Drugs
As online ads abound for diabetes and obesity medications, endocrinologists should be prepared to talk to patients who may be attracted to GLP-1 drug lookalikes and supplements from questionable sources. GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages...
Do Vitamin D Supplements Lower Blood Pressure in Older People with Obesity?
Vitamin D supplements may lower blood pressure in older people with obesity and taking more than the Institutes of Medicine’s (IOM) recommended daily dose does not provide additional health benefits, according to new research published in the Journal of the Endocrine Society. The IOM recommends 600 International Units (IU) per day. Vitamin D deficiency is common...
In the U.S., November is designated as American Diabetes Month. The World Health Organization sets aside November 14th as Diabetes Day. And here in the U.K., we blocked out June 10 – 16, 2024, as Diabetes Week. Globally, many other countries have similar diabetes mellitus recognition events in their calendars. Regardless of the dates on...
